表紙
市場調査レポート

PharmaPoint:ヒトパピローマウイルス(HPV)予防ワクチン - 現在・将来の主要企業

PharmaPoint: Prophylactic Human PapillomaVirus Vaccines - Current and Future Players

発行 GlobalData 商品コード 307137
出版日 ページ情報 英文 40 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
PharmaPoint:ヒトパピローマウイルス(HPV)予防ワクチン - 現在・将来の主要企業 PharmaPoint: Prophylactic Human PapillomaVirus Vaccines - Current and Future Players
出版日: 2014年03月31日 ページ情報: 英文 40 Pages
概要

当レポートでは、急速に成長しているヒトパピローマウイルス(HPV)予防ワクチン市場について調査分析し、新規参入企業を含めた競合情勢に焦点を当てて、市場の見通し、主要企業のプロファイルなどについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 予測
    • 促進要因・障壁

第4章 現在・将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Merck
    • GSK

第5章 付録

図表

目次
Product Code: GDHC1032FPR

GlobalData has released its pharma report, "PharmaPoint: Prophylactic Human PapillomaVirus Vaccines - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Prophylactic Human Papillomavirus Vaccines Market. The report identifies and analyses the key companies shaping and driving the global Prophylactic Human Papillomavirus Vaccines market. The report provides insight into the competitive Prophylactic Human Papillomavirus Vaccines landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Prophylactic Human Papillomavirus Vaccines
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Prophylactic Human Papillomavirus Vaccines sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Prophylactic Human Papillomavirus Vaccines market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Prophylactic Human Papillomavirus Vaccines market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Merck
    • 4.3.2. GSK

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Vaccine Coverage
    • 5.4.2. Vaccine Approval versus Routine Schedule Inclusion
    • 5.4.3. General Pricing Assumptions
  • 5.5. Physicians and Specialists Included in this Study
  • 5.6. About the Author(s)
    • 5.6.1. Author(s)
    • 5.6.2. Therapy Area Director
    • 5.6.3. Global Head of Healthcare
  • 5.7. About GlobalData
  • 5.8. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for HPV Vaccines, 2012-2022
  • Table 2: Global HPV Vaccine Market - Drivers and Barriers, 2014
  • Table 3: Key Companies in the HPV Vaccine Market, 2014
  • Table 4: Merck's HPV Vaccine Portfolio Assessment, 2014
  • Table 5: Merck SWOT Analysis, 2014
  • Table 6: GSK's HPV Vaccine Portfolio Assessment, 2014
  • Table 7: GSK SWOT Analysis, 2014
  • Table 8: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for HPV Vaccines by Region, 2012-2022
  • Figure 2: Company Portfolio Gap Analysis in HPV Vaccines, 2012-2022
Back to Top